New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist

Koshak, Emad A.

doi:10.4103/1817-1737.62468

Cited by 5 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 137 ] Based on this evidence, the Saudi Food and Drug Administration withdrew all LABA monotherapy medications from the Saudi market by the end of 2010. [ 138 ] Therefore, the SINA panel has limited the use of relievers to SABA or formoterol containing combination when SMART approach is used Alternative and generally less-effective strategies include the continuation of ICS as a monotherapy by increasing the dose to the medium-high dose range (Evidence A),[ 137 139 ] and the addition of LTRA to a low-medium dose ICS (Evidence A),[ 140 141 ] especially in patients with concomitant rhinitis. [ 142 ] The addition of sustained release theophylline to a low-medium dose ICS is a possible but not favorable choice (Evidence B)[ 143 ] Tiotropium is a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease (COPD).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2016

View full text Add to dashboard Cite

This is an updated guideline for the diagnosis and management of asthma, developed by the Saudi Initiative for Asthma (SINA) group, a subsidiary of the Saudi Thoracic Society. The main objective of SINA is to have guidelines that are up to date, simple to understand and easy to use by nonasthma specialists, including primary care and general practice physicians. SINA approach is mainly based on symptom control and assessment of risk as it is the ultimate goal of treatment. The new SINA guidelines include updates of acute and chronic asthma management, with more emphasis on the use of asthma control in the management of asthma in adults and children, inclusion of a new medication appendix, and keeping consistency on the management at different age groups. The section on asthma in children is rewritten and expanded where the approach is stratified based on the age. The guidelines are constructed based on the available evidence, local literature, and the current situation in Saudi Arabia. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[129] Based on this evidence, the Saudi Food and Drug Administration withdrew all LABA monotherapy medications from the Saudi market by the end of 2010. [130] Therefore, the SINA panel has limited the use of relievers to SABA or to formoterol when combined with ICSAlternative and generally less effective strategies include the continuation of ICS as a monotherapy by increasing the dose to the medium-high-dose range (Evidence A),[129131] or the addition of LTRA to a low-medium-dose ICS (Evidence A),[132133] especially in patients with concomitant rhinitis. [134] The addition of sustained release theophylline to a low-medium dose ICS is a possible but less favorable choice (Evidence B)[135]Tiotropium is a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease (COPD).…”

Section: Pharmacological Management In Adults and Adolescentmentioning

confidence: 99%

The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2019

View full text Add to dashboard Cite

This is the fourth version of the updated guidelines for the diagnosis and management of asthma, developed by the Saudi Initiative for Asthma (SINA) group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up to date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is now more aligned for different age groups. The guidelines have focused more on personalized approaches reflecting better understanding of disease heterogeneity with integration of recommendations related to biologic agents, evidence-based updates on treatment, and role of immunotherapy in management. The medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

show abstract

“…[60] Based on this evidence, the Saudi FDA withdrew all LABA monotherapy medications from the Saudi market by the end of 2010. [142] Therefore, the SINA panel has limited the use of relievers to SABA.Alternative, but in general less-effective strategies include: the continuation of ICS as a monotherapy by increasing the dose to the medium- to high-dose range (Evidence A),[60143] and the addition of LTRA to a low-medium dose ICS (Evidence A),[144145] especially in patients with concomitant rhinitis. [146] The addition of sustained release theophylline to a low-medium dose ICS is a third alternative choice (Evidence B).…”

Section: Treatment (Pharmacologic) Stepsmentioning

confidence: 99%

Section: Treatment (Pharmacologic) Stepsmentioning

confidence: 99%

The Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2012

View full text Add to dashboard Cite

This an updated guidelines for the diagnosis and management of asthma, developed by the Saudi Initiative for Asthma (SINA) group, a subsidiary of the Saudi Thoracic Society. The main objective of SINA is to have updated guidelines, which are simple to understand and easy to use by non-asthma specialists, including primary care and general practice physicians. This new version includes updates of acute and chronic asthma management, with more emphasis on the use of Asthma Control Test in the management of asthma, and a new section on “difficult-to-treat asthma.” Further, the section on asthma in children was re-written to cover different aspects in this age group. The SINA panel is a group of Saudi experts with well-respected academic backgrounds and experience in the field of asthma. The guidelines are formatted based on the available evidence, local literature, and the current situation in Saudi Arabia. There was an emphasis on patient–doctor partnership in the management that also includes a self-management plan. The approach adopted by the SINA group is mainly based on disease control as it is the ultimate goal of treatment.

show abstract

New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist

Cited by 5 publications

References 4 publications

The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children

The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children

The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children

The Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and children

Contact Info

Product

Resources

About